Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Sarcoma, Alveolar Soft Part 1 Neuroendocrine Tumors 1 Metastatic Neuroendocrine Prostate Cancer 1 Chondrosarcoma 1 Advanced Solid Tumors 1

Interventions

Injections 25 Carboplatin 17 Docetaxel 14 pembrolizumab 12 Paclitaxel 11 Bevacizumab 9 durvalumab 8 Cisplatin 8 Nivolumab 6 Fluorouracil 6 trifluridine tipiracil drug combination 5 tislelizumab 5 linifanib 5 Pemetrexed 5 Oxaliplatin 5 Leucovorin 5 zimberelimab 4 toripalimab 4 talazoparib 4 olaparib 4 Itraconazole 4 Irinotecan 4 Gemcitabine 4 Capecitabine 4 tremelimumab 3 sotorasib 3 sintilimab 3 fludarabine 3 depatuxizumab 3 atezolizumab 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Solid Tumors × Antiemetics × Clear all

NCT06242691 2026-06-05

MK-1200-002

Merck Sharp & Dohme LLC

Phase 1/2 Completed

13 enrolled 21 charts

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡